Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

Grant Name
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Funder
U.S. Department of Health and Human Services
Country or Region
United States
Research Field
Biochemistry, Genetics and Molecular Biology, Genetics,Molecular Biology
Deadline
October 19, 2022
Grant Size
Up to 300,000 USD
Grant Number
PAR-20-225
Description
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrows leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

Funding resources

Purdue Grant Writing Lab: Introduction to Grant Writing Open Link
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal Open Link

Quick share


Add deadline to calendar

October 19, 2022

Have a funding opportunity that you want to list here?

Submit the grant details to support@peeref.com for review and listing.

Related opportunities

Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
Food and Nutrition October 7, 2022 $3,000,000
Doctoral Scholarships
Agriculture June 5, 2023 Upper £1,350,000GBP Lower £90,000GBP Thi...
Smart specialisation, venture capital programme
Agricultural and Biological Sciences December 21, 2023 Up to 1,500,000,000 HUF with total fundi...
Spill Impact Component Project Grants
Natural Resources December 29, 2023 $1,600,500,629
Notice of Intent
Natural Resources May 20, 2024 $200,000